Chinese generic company takes another step along the road to becoming a full-blown originator

China’s Shanghai Fosun Pharmaceutical has announced a cooperation agreement with Switzerland-based biopharmaceutical and research company Sellas Life Sciences Group for the licensing of $533 million worth of IP rights relating to diabetes and cancer…

Get unlimited access to all IAM content